Assenagon Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Assenagon Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-769,336	Closed	-$4.49M	–	1542
2022 Q4	$4.49M	Sell	769,336 -140,554	-15%	-$739K	0.02%	558
2022 Q3	$6.1M	Buy	909,890 +361,047	+66%	+$2.19M	0.02%	443
2022 Q2	$2.31M	Buy	548,843 +516,912	+1,619%	+$2.05M	0.01%	787
2022 Q1	$108K	Sell	31,931 -110,033	-78%	-$349K	﹤0.01%	1379
2021 Q4	$447K	Sell	141,964 -94,403	-40%	-$314K	﹤0.01%	1216
2021 Q3	$773K	Buy	236,367 +94,681	+67%	+$332K	﹤0.01%	971
2021 Q2	$598K	Buy	141,686 +15,654	+12%	+$66.3K	﹤0.01%	1013
2021 Q1	$629K	Buy	+126,032	New	+$1.02M	﹤0.01%	1001
2019 Q3	–	Sell	-109,588	Closed	-$1.31M	–	1126
2019 Q2	$1.31M	Buy	+109,588	New	+$1.18M	0.01%	647

Assenagon Asset Management's CNCE Position: Q1 2023 in Review

Assenagon Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 769,336 shares — an estimated $4.49M sold.

Assenagon Asset Management first reported a position in CNCE in Q2 2019 and held it in 9 quarters. The position peaked at $6.1M in Q3 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Assenagon Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Assenagon Asset Management sold 769,336 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $4.49M.
Assenagon Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2019 and held it in 9 quarters.
Assenagon Asset Management's Concert Pharmaceuticals, Inc. position peaked at $6.1M in Q3 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Assenagon Asset Management's 13F filing for Q1 2023, filed 18 Apr 2023.